Abstract. Alzheimer's disease (AD) is a major clinical concern, and the search for new molecules to combat disease progression remains important. One of the major hallmarks in AD pathogenesis is the hyperphosphorylation of tau and subsequent formation of neurofibrillary tangles. Several kinases are involved in this process. Amongst them, c-Jun N-terminal kinases (JNKs) are activated in AD brains and are also associated with the development of amyloid plaques. This study was designed to investigate the contribution of JNK in tau hyperphosphorylation and whether it may represent a potential therapeutic target for the fight against AD. The specific inhibition of JNK by the cell permeable peptide D-JNKI-1 led to a reduction of p-tau at S202/T205 and S422, two established target sites of JNK, in rat neuronal cultures and in human AD fibroblasts cultures. Similarly, D-JNKI-1 reduced p-tau at S202/T205 in an in vivo model of AD (TgCRND8 mice). Our findings support the fundamental role of JNK in the regulation of tau hyperphosphorylation and subsequently in AD pathogenesis. Sigma Aldrich) was added to the media at 2 days from 105 plating date (2DIV).
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c-Jun N terminal kinases (JNKs) belong to the fam-25 ily of serine and threonine mitogen-activated protein 1 These two authors contributed equally to this work.
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Real-time reverse transcription-PCR
168
Total RNA was isolated from cortical neurons using ratio by 60% both in the cortex (Fig. 4A,B ) and the 380 hippocampus (Fig. 4E,F tau (clone tau-5)/Actin ratio in cortex (Fig. 4A-D) . Tukey's post-hoc test) (±S.E.M.) (Fig. 6B,C) .
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We then evaluated the effect of 
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We demonstrated that, in all three models, JNK inhi- it should be noted that this effect is restricted to control 524 cortical neurons and it is absent in the two other models 525 studied (TgCRND8 mice and human fibroblasts).
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Subsequently we studied phosphorylation of tau by 
